SCHEMBL5047576

SCHEMBL5047576

O=c1[nH]c2cc(F)cc(F)c2nc1CCN1CC[CH]CC1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGLN1 Q9GZT9 1/20 0.37
PARP1 P09874 8/20 0.36
TNKS O95271 2/20 0.34
TNKS2 Q9H2K2 2/20 0.34
KCNH2 Q12809 4/20 0.33
PARP2 Q9UGN5 1/20 0.33
DRD2 P14416 2/20 0.33
HTR2A P28223 2/20 0.33
HTR1A P08908 1/20 0.33
SLC6A2 P23975 1/20 0.32
SLC6A4 P31645 1/20 0.32
SLC6A3 Q01959 1/20 0.32
PDGFRB P09619 1/20 0.32
FGFR1 P11362 1/20 0.32
KDR P35968 1/20 0.32
SSTR5 P35346 2/20 0.31
F10 P00742 1/20 0.31
DGAT1 O75907 1/20 0.31
ADORA2A P29274 1/20 0.31
TPSAB1 Q15661 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3847249 0.82 HRH4 (0.42) EGLN1PARP1KCNH2PARP2SLC6A2
SCHEMBL5047640 0.77 MPO (0.36) PARP1KCNH2DRD2HTR2AHTR1A
SCHEMBL3846941 0.72 KCNH2 (0.47) PARP1KCNH2PARP2HTR2AHTR1A
SCHEMBL5044764 0.72 PARP1 (0.32) PARP1KCNH2PARP2
SCHEMBL5050024 0.70 MPO (0.35) PARP1KCNH2PARP2DRD2HTR2A
SCHEMBL4733245 0.70 NPSR1 (0.46) EGLN1DRD2
SCHEMBL5050047 0.68 KCNH2 (0.35) PARP1KCNH2PARP2DRD2HTR2A
SCHEMBL5051229 0.65 MPO (0.34) PARP1KCNH2DRD2HTR2AHTR1A
SCHEMBL3844281 0.65 PARP1 (0.37) PARP1PARP2DAODDO
SCHEMBL5044755 0.65 ALDH1A1 (0.39) DRD2HTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1893599-A1 COMPOUNDS FOR THE TREATMENT OF MULTI-DRUG RESISTANT BACTERIAL INFECTIONS AstraZeneca AB (SE) 2008-03-05 EP disclosed
WO-2006134378-A1 COMPOUNDS FOR THE TREATMENT OF MULTI-DRUG RESISTANT BACTERIAL INFECTIONS ASTRAZENECA AB (SE) 2006-12-21 WO disclosed